Related references
Note: Only part of the references are listed.Vascular endothelial growth factor contributes to lung vascular hyperpermeability in sepsis-associated acute lung injury
Kengo Tomita et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2020)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2013)
Bevacizumab Maintenance in Patients with Advanced Non-Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory Analysis
Ariel Lopez-Chavez et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Andre Bacellar Costa Lima et al.
PLOS ONE (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
Lucio Crino et al.
LANCET ONCOLOGY (2010)
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
J. Tol et al.
INVESTIGATIONAL NEW DRUGS (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
